Bioharvest Sciences Inc. (BHST)
Summary
BioHarvest Sciences Inc. (BHST) Q1 2026 Earnings Call Transcript
BioHarvest Sciences Inc. (BHST) Q1 2026 Earnings Call Transcript
BioHarvest Sciences Q1 Earnings Call Highlights
BioHarvest Sciences NASDAQ: BHST reported higher first-quarter revenue and reiterated its 2026 outlook as management detailed a broader reorganization around two business lines: its direct-to-consumer VINIA products business and its contract development and manufacturing organization, or CDMO, platform.
BioHarvest Sciences Q1 revenue climbs as it expands botanical synthesis pipeline
BioHarvest Sciences Inc (NASDAQ:BHST, FRA:8MV0) reported an 8% jump in first quarter revenue as the company advanced several contract development and manufacturing organization (CDMO) projects and expanded its direct-to-consumer wellness business. The company posted first quarter revenue of $8.5 million, up from $7.9 million a year earlier, while maintaining its full-year revenue guidance range of $42 million to $48 million.
Bioharvest Sciences Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| MA Marie-Andree Alain Federation des caisses Desjardins du Quebec | 76 | $469.68 | $243.2 | -$226.48 | -48.22% |
Bioharvest Sciences Inc. (BHST) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Bioharvest Sciences Inc. ever had a stock split?
Bioharvest Sciences Inc. Profile
| Biotechnology Industry | Healthcare Sector | Ilan Sobel CEO | NASDAQ (NMS) Exchange | 09076J207 CUSIP |
| CA Country | 87 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
BioHarvest Sciences Inc. is a trailblazer in the biotechnology industry, focusing on the innovative development of botanical synthesis platform technology. This advanced technology enables the company to cultivate essential ingredients found in various fruits and plants without the necessity of growing the plants themselves. Positioned at the intersection of science and nature, BioHarvest Sciences is committed to bringing forth therapeutic solutions that are both science-based and clinically proven, catering to the nutraceuticals and pharmaceuticals sectors. In addition to its role as a product innovator, the company extends its expertise to serve as a contract development and production organization (CDMO), offering its services to clients in need of diverse molecules. With operations spanning across Israel and the United States, and headquartered in Vancouver, Canada, BioHarvest Sciences Inc. is pioneering a sustainable approach to biotechnology, aimed at enhancing health and wellness through its unique platform.
Products and Services
- VINIA
VINIA is a premier product from BioHarvest Sciences Inc., featuring a red grape cell dietary supplement that is rich in the natural matrix of polyphenols found in red grapes. This innovative product exemplifies the company's capability to harness the power of botanical synthesis technology, delivering the health benefits of red grapes in a concentrated form. VINIA is designed to support cardiovascular health, antioxidant activity, and overall wellness, reflecting BioHarvest Sciences Inc.'s commitment to leveraging natural ingredients for maximum health benefits.
- Contract Development and Production Organization (CDMO) Services
As a CDMO, BioHarvest Sciences Inc. offers a range of specialized services to clients seeking to develop and produce various molecules. This aspect of the company's operations showcases its technical expertise and flexible capability to meet diverse client needs. From initial development stages through to production, BioHarvest Sciences Inc. works closely with its partners to ensure the highest standards of quality and efficiency are met, thereby reinforcing its position as a trusted collaborator in the biotechnology and pharmaceutical industries.
